The 2019 Lyfebulb-Helsinn Innovation Award

Celgene will host Addressing Unmet Needs in MS: An Innovation Challenge,
Summit, NJ
June 12 & 13, 2019


March 18, 2019
Introductory meetings and activities
March 19, 2019
Pitch presentations, gala dinner and award winner announcement

The Winner

UE LifeSciences Inc.

Mihir Shah is a visionary entrepreneur addressing global health disparities by translating scientific discoveries into affordable and scalable med-tech solutions that improve outcomes. For over 15 years, he’s led the commercialization of several medical innovations impacting many lives. He is the Founder and President of UE Lifesciences, a fast-growing multi-national startup making the hope of cancer early detection a reality with the award-winning innovations, iBreastExam and cervAIcal, benefitting over 400,000 women in 10 countries.

A two-time TED speaker, Mihir’s work has been featured in The New York Times, BBC, and other notable publications. As an adjunct faculty member, Mihir teaches Entrepreneurship in Biomedical Engineering at Drexel University.

Mihir Shah
Founder and President


Ten finalists will compete at the second annual Lyfebulb-Helsinn Innovation Summit. The second annual Lyfebulb-Helsinn Innovation Award will be presented to an exceptional innovator with outstanding entrepreneurial potential to commercialize creative ideas to better manage cancer using drugs, medical devices or healthcare information technology.


Honorable Mention

Genenta Science

Pierluigi is co-founder and Chairman & CEO at Genenta Science, a clinical stage immune-gene therapy company, and a spinoff from Prof. Luigi Naldini and San Raffaele Milano, which has raised $20M in two rounds. Currently, the company has phase 1/2 trials ongoing in multiple myeloma and glioblastoma. Genenta has labs and an office in Milano and an office at Alexandria Center LaunchLabs, New York.

Pierluigi is a serial entrepreneur and investor in biotech, for example he invested in Ethical Oncology Science (EOS), a company acquired by Clovis Oncology (Nasdaq: CVLS) for $470M in 2013. He is a co-founder and Board Member at Altheia Science, an autoimmune diseases startup that raised $20M for its Series A round in 2018.

Regarding his personal experience, Pierluigi says, “I’m not a scientist, I’m an entrepreneur in biotech with a financial background. I really saw a cancer cell for the first time when my mom was diagnosed in 2007, a few months before my marriage. She is here with us today and she enjoys spending time her granddaughter, thanks to clinical research.”

He is a former VC, e.g. co-founder and CEO at Quantica SGR, Venture Consultant at Sofinnova Partners, co-founder and Investment Advisor at Axòn Capital, and co-founder and advisor at AurorA-TT. He is a board member of Italia Startup (Italian Association for startups) and Assobiotec (Italian Association of biotech companies). He is a member of Italian Angels for Biotech (business angel group) and Confindustria Life Sciences and Cluster Life Sciences – Lombardia.

Pierluigi Paracchi
Chairman and CEO



Carolyn R. “Bo” Aldigé

Founder and CEO at Prevent Cancer Foundation

Håkan Åström, Med.Dr.h.c.

Board member of Rhenman & Partners Asset Management, Karo Pharma AB and Chairman of the Board of PledPharma AB

Georges Garnier, MD

Head of Hematology and Oncology Department, Princess Grace Hospital, Monaco

David Hunt

CEO, Havas Lynx Group

Professor Patrick Rampal, MD

President, Scientific Center of Monaco

Stephen Squinto, PhD

Venture Partner at Orbimed, Co-Founder at Alexion, and Co-Founder & Chairman at Lyfebulb